EA200500899A1 - Антагонисты аденозиндифосфатного рецептора тромбоцитов - Google Patents

Антагонисты аденозиндифосфатного рецептора тромбоцитов

Info

Publication number
EA200500899A1
EA200500899A1 EA200500899A EA200500899A EA200500899A1 EA 200500899 A1 EA200500899 A1 EA 200500899A1 EA 200500899 A EA200500899 A EA 200500899A EA 200500899 A EA200500899 A EA 200500899A EA 200500899 A1 EA200500899 A1 EA 200500899A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
diphosphate
addrose
antagonists
platelet receptor
Prior art date
Application number
EA200500899A
Other languages
English (en)
Inventor
Джуди Брайант
Брад Букман
Имадул Ислам
Раджу Мохан
Майкл Морриссей
Гуопин Вэй
Вэй Сюй
Шеньдон Юань
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200500899A1 publication Critical patent/EA200500899A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

В заявке описаны соединения следующей формулы:в которой m, n, R, R, R, Rи R, описанные в настоящем изобретении, применимы в качестве ингибиторов аденозиндифосфата тромбоцитов. В заявке также описаны фармацевтические композиции, содержащие эти соединения, способы применения этих соединений в качестве антитромботических средств и способы синтеза этих соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500899A 2002-12-11 2003-12-09 Антагонисты аденозиндифосфатного рецептора тромбоцитов EA200500899A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43279202P 2002-12-11 2002-12-11
PCT/US2003/039079 WO2004052366A1 (en) 2002-12-11 2003-12-09 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists

Publications (1)

Publication Number Publication Date
EA200500899A1 true EA200500899A1 (ru) 2006-02-24

Family

ID=32507994

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500899A EA200500899A1 (ru) 2002-12-11 2003-12-09 Антагонисты аденозиндифосфатного рецептора тромбоцитов

Country Status (23)

Country Link
US (2) US7056923B2 (ru)
EP (1) EP1578423B1 (ru)
JP (1) JP4662777B2 (ru)
KR (1) KR20050085580A (ru)
CN (1) CN1747732A (ru)
AP (1) AP2005003363A0 (ru)
AT (1) ATE477800T1 (ru)
AU (1) AU2003297763A1 (ru)
BR (1) BR0317222A (ru)
CA (1) CA2507657C (ru)
DE (1) DE60333866D1 (ru)
EA (1) EA200500899A1 (ru)
EC (1) ECSP055912A (ru)
ES (1) ES2348942T3 (ru)
MX (1) MXPA05006302A (ru)
NO (1) NO20053335L (ru)
NZ (1) NZ540872A (ru)
OA (1) OA12970A (ru)
PL (1) PL377053A1 (ru)
RS (1) RS20050450A (ru)
UA (1) UA83648C2 (ru)
WO (1) WO2004052366A1 (ru)
ZA (1) ZA200505492B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
DE602004027409D1 (de) * 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
DE102006020385A1 (de) * 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) * 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
MY148901A (en) 2007-06-18 2013-06-14 Sanofi Aventis Pyrrole derivatives as p2y12 antagonists
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
US8288385B2 (en) 2009-04-08 2012-10-16 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
CN102304108B (zh) * 2011-06-28 2013-11-06 中国药科大学 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途
CN104151235B (zh) * 2014-08-07 2016-01-20 南阳师范学院 一种喹啉衍生物制备方法
EP3981774A1 (en) 2016-09-22 2022-04-13 Idorsia Pharmaceuticals Ltd Crystalline forms
JP2020510043A (ja) 2017-03-15 2020-04-02 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｙ１２受容体アンタゴニストの皮下投与
CN112062687B (zh) * 2020-09-02 2023-11-21 上海信谊万象药业股份有限公司 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60474A (en) * 1866-12-18 Pbtee chick
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
KR920703558A (ko) 1990-11-15 1992-12-18 원본미기재 메타-치환 페닐알라닌 유도체
EP0635008B1 (de) * 1993-02-10 2002-09-04 Pentapharm A.G. Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
KR0173034B1 (ko) * 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists

Also Published As

Publication number Publication date
BR0317222A (pt) 2005-11-01
CA2507657A1 (en) 2004-06-24
NO20053335L (no) 2005-09-07
CA2507657C (en) 2011-05-31
JP2006511519A (ja) 2006-04-06
EP1578423B1 (en) 2010-08-18
WO2004052366A1 (en) 2004-06-24
US20060122188A1 (en) 2006-06-08
AU2003297763A1 (en) 2004-06-30
WO2004052366A9 (en) 2005-06-23
KR20050085580A (ko) 2005-08-29
DE60333866D1 (de) 2010-09-30
JP4662777B2 (ja) 2011-03-30
ECSP055912A (es) 2005-11-22
NO20053335D0 (no) 2005-07-08
RS20050450A (en) 2007-08-03
US7084142B2 (en) 2006-08-01
AP2005003363A0 (en) 2005-09-30
US7056923B2 (en) 2006-06-06
ATE477800T1 (de) 2010-09-15
US20040138229A1 (en) 2004-07-15
ZA200505492B (en) 2006-03-29
PL377053A1 (pl) 2006-01-23
EP1578423A1 (en) 2005-09-28
NZ540872A (en) 2007-08-31
MXPA05006302A (es) 2005-08-29
UA83648C2 (ru) 2008-08-11
OA12970A (en) 2006-10-13
ES2348942T3 (es) 2010-12-17
CN1747732A (zh) 2006-03-15

Similar Documents

Publication Publication Date Title
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
SE0101675D0 (sv) Novel composition
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
EA200200770A1 (ru) Производные пурина
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DE60314623D1 (de) Substituierte pyrazolopyrimidine
EA200200912A1 (ru) Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
ATE413388T1 (de) Muskarin antagonisten
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
EA200000910A1 (ru) Азабициклические лиганды рецепторов 5нт1